secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIGAND PHARMACEUTICALS INC (LGND)
CIK:        0000886163
Form:       8-K
Filed at:   2026-06-09T20:02:51+00:00
Accession:  0000886163-26-000038
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Ligand shareholders elect directors, approve equity plan amendment at annual meeting
--------------------------------------------------------------------------------

- All eight director nominees elected; Martine Zimmermann received 17,319,859 votes for, highest of the slate.
- Ernst & Young ratified as independent auditor for FY2026 with 18,526,515 votes for, 257,924 against.
- Non-binding say-on-pay resolution approved: 16,497,712 for, 1,021,948 against, 14,099 abstentions.
- Amendment and restatement of 2002 Stock Incentive Plan approved: 16,643,281 for, 870,556 against.
- All votes had substantial majority support; no director received less than 16.2M votes for.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886163/000088616326000038/0000886163-26-000038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886163/000088616326000038/lgnd-20260605.htm
  HTML page:      https://secwatch.observer/filing/0000886163-26-000038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer